Thomas Mavrakanas
McGill University Health Centre/Research Institute of the McGill University Health Centre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Thomas Mavrakanas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06182839 · Canagliflozin in Advanced Renal Disease With MRI EndpointsMcGill University Health Centre/Research Institute of the McGill University Health Centre · recruiting · ESRD, CKD Stage 4, CKD Stage 5 · principal investigator
- Ph4NCT05309785 · Safety and Efficacy of Canagliflozin in Advanced CKDMcGill University Health Centre/Research Institute of the McGill University Health Centre · completed · ESRD, CKD Stage 4, CKD Stage 5 · principal investigator
- Ph4NCT05305495 · Empagliflozin in Acute Heart FailureMcGill University Health Centre/Research Institute of the McGill University Health Centre · completed · Acute Heart Failure, Chronic Kidney Diseases · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:56 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- The Impact of Intradialytic Pedaling Exercise on Arterial Stiffness: A Pilot Randomized Controlled Trial in a Hemodialysis Population.Am J Hypertens · 201831 citationsRCR 2.0
- Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes.Clin Transplant · 201730 citationsRCR 1.7
- Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.Diabetes Obes Metab · 20246 citationsRCR 0.8
- Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.Clin Pharmacokinet · 20254 citationsRCR 1.2
- Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney Disease.Clin Pharmacokinet · 20251 citationsRCR 0.2